Aclarion’s Nociscan Expands Clinical Utility with Real-World Evidence and Novel Pain Treatment Application
Event summary
- Aclarion presented two abstracts at the ASPN annual meeting on July 21, 2026, showcasing Nociscan’s growing role in chronic low back pain management.
- First study by Timothy Davis, MD, demonstrated successful integration of Nociscan into clinical workflows for identifying symptomatic lumbar discs.
- Second case study by Kristen and Brian Durkin highlighted Nociscan’s use in guiding basivertebral nerve ablation (BVNA) in a patient without classic Modic changes, resulting in 95% pain relief.
The big picture
Aclarion’s presentation underscores the growing role of advanced diagnostic tools like Nociscan in chronic pain management, particularly as healthcare systems seek more precise, non-invasive solutions. The case study demonstrating 95% pain relief post-BVNA highlights the potential for MRS technology to expand into new procedural applications, positioning Aclarion at the forefront of a shift toward biomarker-driven pain diagnostics.
What we're watching
- Clinical Adoption Pace
- How quickly Nociscan will be integrated into standard clinical workflows for chronic low back pain management.
- Procedure Expansion
- Whether Nociscan’s utility in guiding BVNA and other procedures will drive broader adoption beyond traditional MRI-based diagnostics.
- Real-World Evidence Impact
- The extent to which real-world evidence studies will influence payer coverage and physician prescribing behavior for Nociscan.